niacinamide has been researched along with Atrophy in 9 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To date, sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)." | 7.81 | Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib. ( Bruckner, T; Ganten, MK; Ganten, TM; Koschny, R; Schuessler, M, 2015) |
| "Pancreatic atrophy occurred in many HCC patients after 2 y of treatment with sorafenib." | 7.81 | Long-term therapy with sorafenib is associated with pancreatic atrophy. ( Chen, MS; Li, SP; Pawlik, TM; Spolverato, G; Xu, L; Zhang, YJ; Zhao, J; Zhou, DS, 2015) |
| " We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib." | 7.79 | Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013) |
| "Sorafenib is a multi-targeted tyrosine kinase inhibitor licensed for the treatment of hepatocellular carcinoma and renal cell carcinoma." | 7.77 | Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. ( Eskens, FA; Mathijssen, RH; Peeters, RP; van der Lugt, A; van Doorn, L; Visser, TJ, 2011) |
| "To date, sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)." | 3.81 | Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib. ( Bruckner, T; Ganten, MK; Ganten, TM; Koschny, R; Schuessler, M, 2015) |
| "Pancreatic atrophy occurred in many HCC patients after 2 y of treatment with sorafenib." | 3.81 | Long-term therapy with sorafenib is associated with pancreatic atrophy. ( Chen, MS; Li, SP; Pawlik, TM; Spolverato, G; Xu, L; Zhang, YJ; Zhao, J; Zhou, DS, 2015) |
| " We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib." | 3.79 | Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013) |
| "Sorafenib is a multi-targeted tyrosine kinase inhibitor licensed for the treatment of hepatocellular carcinoma and renal cell carcinoma." | 3.77 | Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. ( Eskens, FA; Mathijssen, RH; Peeters, RP; van der Lugt, A; van Doorn, L; Visser, TJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diani-Moore, S | 1 |
| Shoots, J | 1 |
| Singh, R | 1 |
| Zuk, JB | 1 |
| Rifkind, AB | 1 |
| Shawa, H | 1 |
| Busaidy, NL | 1 |
| Schellingerhout, D | 1 |
| Habra, MA | 1 |
| Hescot, S | 1 |
| Vignaux, O | 1 |
| Goldwasser, F | 1 |
| Ganten, MK | 1 |
| Schuessler, M | 1 |
| Bruckner, T | 1 |
| Ganten, TM | 1 |
| Koschny, R | 1 |
| Xu, L | 1 |
| Zhou, DS | 1 |
| Zhao, J | 1 |
| Spolverato, G | 1 |
| Zhang, YJ | 1 |
| Li, SP | 1 |
| Chen, MS | 1 |
| Pawlik, TM | 1 |
| Lee, J | 1 |
| Yee, ST | 1 |
| Kim, JJ | 1 |
| Choi, MS | 1 |
| Kwon, EY | 1 |
| Seo, KI | 1 |
| Lee, MK | 1 |
| van Doorn, L | 1 |
| Eskens, FA | 1 |
| Visser, TJ | 1 |
| van der Lugt, A | 1 |
| Mathijssen, RH | 1 |
| Peeters, RP | 1 |
| Feng, Y | 1 |
| Paul, IA | 1 |
| LeBlanc, MH | 1 |
9 other studies available for niacinamide and Atrophy
| Article | Year |
|---|---|
NAD
Topics: Animals; Atrophy; Cell Line; Chick Embryo; Dioxins; Fatty Liver; NAD; Niacinamide; Poly(ADP-ribose) | 2017 |
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged | 2013 |
Applied dermatology: Postcard presentation: A dog with claw atrophy.
Topics: Animals; Anti-Bacterial Agents; Atrophy; Dog Diseases; Dogs; Fatty Acids, Unsaturated; Female; Hoof | 2012 |
Pancreatic atrophy--a new late toxic effect of sorafenib.
Topics: Atrophy; Diarrhea; Humans; Niacinamide; Pancreas; Phenylurea Compounds; Protein Kinase Inhibitors; P | 2013 |
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; Female; Humans; | 2015 |
Long-term therapy with sorafenib is associated with pancreatic atrophy.
Topics: Aged; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; China; Cohort Studies; Female; Huma | 2015 |
Ursolic acid ameliorates thymic atrophy and hyperglycemia in streptozotocin-nicotinamide-induced diabetic mice.
Topics: Animals; Atrophy; Blood Glucose; Body Weight; Cell Proliferation; Cytokines; Diabetes Mellitus, Expe | 2010 |
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Atrophy; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; | 2011 |
Nicotinamide reduces hypoxic ischemic brain injury in the newborn rat.
Topics: Animals; Animals, Newborn; Apoptosis; Atrophy; Body Temperature; Brain; Brain Infarction; Carotid St | 2006 |